About Cogent Biosciences
Cogent Biosciences, Inc., formerly Unum Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing precision therapies for genetically defined diseases. The Company also engaged in developing curative cell therapies for solid tumors. Its proprietary technology includes bolt-on chimeric receptor (BOXR), designed to overcome resistance of the solid tumor microenvironment (TME) to T cell attack. The Company also developed product candidates using its proprietary technology, antibody-coupled T cell receptor (ACTR), an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability. Its preclinical program offers, BOXR1030, for the treatment of solid tumor cancers and PLX9486, is a tyrosine kinase inhibitor that is designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17 to treat systemic mastocytosis and gastrointestinal stromal tumors (GIST) patients.